Xenon Pharmaceuticals (XENE) Insider & Congress Trades

Smart money at a glance

Filings to Nov 9, 2026

Net buying: insiders sold $1.1M and bought $1.7M on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.

Company insidersForm 4, 90 days: +$615K net
CongressSTOCK Act, 180 days: None
Big funds13F, quarter ended Jun 30, 2026: 3 added, 0 cut
Federal contractsUSAspending.gov, 12 months: No awards

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

Unlock the full results

Questions about XENE filings

Are insiders buying or selling Xenon Pharmaceuticals Inc (XENE) stock?

Net buying: insiders sold $1.1M and bought $1.7M of XENE stock on the open market in the 90 days to Nov 9, 2026, according to SEC Form 4 filings. $426K of the sales were made under pre-set Rule 10b5-1 trading plans. The largest was Mortimer, Ian (President & CEO), who bought $1.1M. The latest filing was on Oct 1, 2026.

Which members of Congress have traded XENE recently?

None. No member of Congress disclosed a XENE trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this XENE smart-money data?

This summary uses filings available on Nov 9, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.

13F: filed up to 45 days late.

Smart money on XENE

Lean long2 sources:
- Insiders
- Funds

Top traders
No tracked positions at the last update
Insiders
Lean long2 buys · 1 sale
1 of 3 on scheduled plans. Form 4 filings.
Politicians
No recent politician filings found
Funds
Lean long3 added · 0 trimmed
Quarter-end 13F holdings changes, not live trades. A trim is not a short.
Fin-fluencers
No recent posts found

Each bar is 100% of that source’s money. The notch marks an even split.

Lean is the direction of the latest moves. Descriptive, not advice.

Questions about XENE filings

Are insiders buying or selling Xenon Pharmaceuticals Inc (XENE) stock?

Which members of Congress have traded XENE recently?

None. No member of Congress disclosed a XENE trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this XENE smart-money data?

Funds

What funds are doing

5 moves · 6 mo

Buys/Adds$209.5MSells/Trims$16.7M

Buys/Adds (3)

TS
Two Sigma
Q2 2026 13F
$63.9M
added
Signals like this: n=13773, 53% finished lower at D15, median -0.4% vs SPY -0.4%
MW
Marshall Wace
Q2 2026 13F
$41.6M
bought
Signals like this: n=3228, 54% finished lower at D15, median -0.8% vs SPY -0.4%
BO
Bank of America
Q2 2026 13F
$9.0M
added
Signals like this: n=13773, 53% finished lower at D15, median -0.4% vs SPY -0.4%

2 more moves

Pro opens all of them for $16.50/month, paid yearly.

Unlock all 2 moves

Unlock everything for $29/month

Unlock for $29/month

Earnings

Results versus expectations

Documents

Quarterly report10-Q Annual report10-K Every filing

Last report

Aug 6, 2026

Period ending

Jun 30, 2026

Earnings per share

Unavailable

EPS comparison unavailable

Revenue (6M)

$0.00

6M ended Jun 30, 2026 · SEC filing

Next report

Estimated report: Nov 9, 2026, today

Estimates as of Nov 9, 2026

EPS expected

-$1.14

-$1.29 to -$0.94

Last 30 days

1up0down

Analysts raising estimates

Estimate drift

+0.01

Change in 30 days

Previous reports

Quarter / reported	Earnings per share	Beat or miss	Revenue / income	Revenue vs last year
Sep 30, 2026Reported Nov 2, 2026	Not on file	No estimate	Not on file	Not on file
Jun 30, 2026Reported Aug 6, 2026	-$1.11est. -$1.16	+4.41%beat	$0.00SEC filing	No year-ago quarter
Mar 31, 2026Reported May 7, 2026	-$1.17est. -$1.20	+2.29%beat	$0.00SEC filing	-100.0%from $7.5M
Dec 31, 2025Reported Feb 26, 2026	-$1.31est. -$1.21	-8.67%miss	$0.00Yahoo Finance	No year-ago quarter
Sep 30, 2025Reported Nov 3, 2025	-$1.15est. -$1.16	+1.23%beat	$0.00SEC filing	No year-ago quarter
Jun 30, 2025Reported Aug 11, 2025	-$1.07est. -$0.99	-8.08%miss	$0.00SEC filing	No year-ago quarter
Mar 31, 2025Reported May 12, 2025	-$0.83est. -$0.90	+7.78%beat	$7.5MSEC filing	No year-ago quarter
Dec 31, 2024Reported Feb 27, 2025	-$0.84est. -$0.84	-0.10%in line	$0.00 · FYSEC filing	No year-ago quarter

Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.

Open: $37.68
High: $39.20
Low: $37.15
Prev close: $37.68
52-wk high: $72.66
52-wk low: $33.38
Mkt cap: $3.79B
ROE: -43.6%
Beta: 0.08
P/B: 3.1x
Profit margin: +0.0%
Op margin: +0.0%

Fundamentals

Is the business strong?

This company is running thin margins.

Net margin: 0.0%
Market cap: $3.8B

Valuation

P/B3.05

Quality

Operating margin0.0%
ROE-43.6%
ROA-28.0%

Growth

Beta0.08

Technicals

Price structure

This stock's price action is mixed.

Trend

Mixed

55 / 100

RSI 14

70balanced

20D volatility

41%annualized

52-week range

$39.17

$33.38$72.66

20D support

$33.38recent floor

20D resistance

$39.58recent ceiling

Returns

5D +4.7%20D +7.5%60D -39.0%

Price vs moving averages

SMA20 +7.9%SMA50 -9.0%SMA200 -25.1%

Volume pace

0.42xvs prior 20D

Smart money at a glance

Filings to Nov 9, 2026

Net buying: insiders sold $1.1M and bought $1.7M on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.

Company insidersForm 4, 90 days: +$615K net
CongressSTOCK Act, 180 days: None
Big funds13F, quarter ended Jun 30, 2026: 3 added, 0 cut
Federal contractsUSAspending.gov, 12 months: No awards

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

Unlock the full results

Questions about XENE filings

Are insiders buying or selling Xenon Pharmaceuticals Inc (XENE) stock?

Which members of Congress have traded XENE recently?

None. No member of Congress disclosed a XENE trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this XENE smart-money data?

13F: filed up to 45 days late.

Smart money on XENE

Lean long2 sources:
- Insiders
- Funds

Top traders
No tracked positions at the last update
Insiders
Lean long2 buys · 1 sale
1 of 3 on scheduled plans. Form 4 filings.
Politicians
No recent politician filings found
Funds
Lean long3 added · 0 trimmed
Quarter-end 13F holdings changes, not live trades. A trim is not a short.
Fin-fluencers
No recent posts found

Each bar is 100% of that source’s money. The notch marks an even split.

Lean is the direction of the latest moves. Descriptive, not advice.

Questions about XENE filings

Are insiders buying or selling Xenon Pharmaceuticals Inc (XENE) stock?

Which members of Congress have traded XENE recently?

None. No member of Congress disclosed a XENE trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this XENE smart-money data?

Funds

What funds are doing

5 moves · 6 mo

Buys/Adds$209.5MSells/Trims$16.7M

Buys/Adds (3)

TS
Two Sigma
Q2 2026 13F
$63.9M
added
Signals like this: n=13773, 53% finished lower at D15, median -0.4% vs SPY -0.4%
MW
Marshall Wace
Q2 2026 13F
$41.6M
bought
Signals like this: n=3228, 54% finished lower at D15, median -0.8% vs SPY -0.4%
BO
Bank of America
Q2 2026 13F
$9.0M
added
Signals like this: n=13773, 53% finished lower at D15, median -0.4% vs SPY -0.4%

2 more moves

Pro opens all of them for $16.50/month, paid yearly.

Unlock all 2 moves

Unlock everything for $29/month

Unlock for $29/month

Earnings

Results versus expectations

Documents

Quarterly report10-Q Annual report10-K Every filing

Last report

Aug 6, 2026

Period ending

Jun 30, 2026

Earnings per share

Unavailable

EPS comparison unavailable

Revenue (6M)

$0.00

6M ended Jun 30, 2026 · SEC filing

Next report

Estimated report: Nov 9, 2026, today

Estimates as of Nov 9, 2026

EPS expected

-$1.14

-$1.29 to -$0.94

Last 30 days

1up0down

Analysts raising estimates

Estimate drift

+0.01

Change in 30 days

Previous reports

Quarter / reported	Earnings per share	Beat or miss	Revenue / income	Revenue vs last year
Sep 30, 2026Reported Nov 2, 2026	Not on file	No estimate	Not on file	Not on file
Jun 30, 2026Reported Aug 6, 2026	-$1.11est. -$1.16	+4.41%beat	$0.00SEC filing	No year-ago quarter
Mar 31, 2026Reported May 7, 2026	-$1.17est. -$1.20	+2.29%beat	$0.00SEC filing	-100.0%from $7.5M
Dec 31, 2025Reported Feb 26, 2026	-$1.31est. -$1.21	-8.67%miss	$0.00Yahoo Finance	No year-ago quarter
Sep 30, 2025Reported Nov 3, 2025	-$1.15est. -$1.16	+1.23%beat	$0.00SEC filing	No year-ago quarter
Jun 30, 2025Reported Aug 11, 2025	-$1.07est. -$0.99	-8.08%miss	$0.00SEC filing	No year-ago quarter
Mar 31, 2025Reported May 12, 2025	-$0.83est. -$0.90	+7.78%beat	$7.5MSEC filing	No year-ago quarter
Dec 31, 2024Reported Feb 27, 2025	-$0.84est. -$0.84	-0.10%in line	$0.00 · FYSEC filing	No year-ago quarter

Open: $37.68
High: $39.20
Low: $37.15
Prev close: $37.68
52-wk high: $72.66
52-wk low: $33.38
Mkt cap: $3.79B
ROE: -43.6%
Beta: 0.08
P/B: 3.1x
Profit margin: +0.0%
Op margin: +0.0%

Fundamentals

Is the business strong?

This company is running thin margins.

Net margin: 0.0%
Market cap: $3.8B

Valuation

P/B3.05

Quality

Operating margin0.0%
ROE-43.6%
ROA-28.0%

Growth

Beta0.08

Technicals

Price structure

This stock's price action is mixed.

Trend

Mixed

55 / 100

RSI 14

70balanced

20D volatility

41%annualized

52-week range

$39.17

$33.38$72.66

20D support

$33.38recent floor

20D resistance

$39.58recent ceiling

Returns

5D +4.7%20D +7.5%60D -39.0%

Price vs moving averages

SMA20 +7.9%SMA50 -9.0%SMA200 -25.1%

Volume pace

0.42xvs prior 20D

Xenon Pharmaceuticals Inc

Smart money at a glance

What do analysts expect?

Questions about XENE filings

Smart money on XENE

Questions about XENE filings

What funds are doing

What insiders are doing

How top traders are positioned

Unlock everything for $29/month

Results versus expectations

Estimated report: Nov 9, 2026, today

Previous reports

Is the business strong?

Price structure

Ask it in Claude or ChatGPT.

Xenon Pharmaceuticals Inc

Smart money at a glance

What do analysts expect?

Questions about XENE filings

Smart money on XENE

Questions about XENE filings

What funds are doing

What insiders are doing

How top traders are positioned

Unlock everything for $29/month

Results versus expectations

Estimated report: Nov 9, 2026, today

Previous reports

Is the business strong?

Price structure

Ask it in Claude or ChatGPT.

Xenon Pharmaceuticals Inc

Overview

Questions about XENE filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Ask it in Claude or ChatGPT.

Xenon Pharmaceuticals Inc

Overview

Questions about XENE filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Ask it in Claude or ChatGPT.